Type 2 Diabetes Center
The authors conclude that the findings point to a key role in type 2 diabetes for endocannabinoid-induced inflammasome activation in macrophages, and identify cannabinoid receptors on macrophages as a new therapeutic target. To understand type 2 diabetes, a public health threat that affects young and old alike, we need to consider all the factors at play, said Monica Skarulis, M.D., staff clinician at National Institute of Diabetes and Digestive and Kidney Diseases and co-author. We hope that what weve learned from this research will help us develop new strategies to prevent and treat the condition. In addition to Dr. Kunos team of NIAAA scientists and Dr. Skarulis, co-authors on the study included researchers from the University of Colorado Medical Campus, Aurora, and the University of Massachusetts Medical School, Worcester. The National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health, is the primary U.S.
For the original version including any supplementary images or video, visit http://www.nih.gov/news/health/aug2013/niaaa-19.htm
Walking to Work Cuts Obesity, Diabetes Risk WEDNESDAY, Aug. 7, 2013 (MedPage Today) Active modes of traveling to work, such as walking or biking, w… Children with Type 2 Diabetes: An Alarming Trend Nearly 3,700 children and adolescents under age 20 are diagn… Eating Smart for Diabetes: Are You Carb Savvy? You definitely dont need to follow an extreme low-carb diet to manage diabetes, but eating carbohy…
For the original version including any supplementary images or video, visit http://www.everydayhealth.com/conditions/type-2-diabetes
Important to weigh risks, benefits of anti-diabetes drug, experts say
Use of pioglitazone should ideally be stopped if a patient gains 4 kg or more in three months and sees no clinical benefit from the drug. If this drug is used without any monitoring, patients will definitely have small complications,” said Mutha, who is also the founder-president of the Diabetes Care and Research Foundation. Pioglitazone as such is always an add-on therapy in type II diabetes patients who have poor control of the disease through other drugs like sulphonylurea and metformin , he added. The Union government had suspended the manufacture for sale, sale and distribution of the drug pioglitazone and formulations containing pioglitazone for human use vide Gazette Notification GSR 379 (E) dated June 18, 2013, as certain reports published in medical journals raised safety concerns on continued use of the drug. However, the Drugs Technical Advisory Board (DTAB) recommended that the suspension of the manufacture and sale of the drug be revoked on the opinion of an expert committee constituted for the purpose. It recommended, however, that the drug should be allowed to be marketed with a boxed warning and should also be put under the focus of the pharmacovigilance programme.
For the original version including any supplementary images or video, visit http://timesofindia.indiatimes.com/city/pune/Important-to-weigh-risks-benefits-of-anti-diabetes-drug-experts-say/articleshow/21966096.cms